

## Research Compliance Activity and Turn-Around-Time (TAT) Summary Report

Fiscal Year 2014-2015 (7/1/2014 to 6/30/2015)

*TAT calculated from submission date to date of approval. TAT not calculated for continuing reviews.*

| Institutional Biosafety Committee (IBC) - IUPUI |        |        |        |        |        |        |        |        |            |                   |
|---|--------|--------|--------|--------|--------|--------|--------|--------|------------|-------------------|
|   | Q1 TAT |        | Q2 TAT |        | Q3 TAT |        | Q4 TAT |        | FY-END TAT |                   |
|   | Mean   | Median | Mean   | Median | Mean   | Median | Mean   | Median | Mean       | Median            |
| <b>Full Board</b>                               |        |        |        |        |        |        |        |        |            | <b>Full Board</b> |
| New Studies - Full Board (to review)            | 27.0   | 24.0   | 31.8   | 33.5   | 26.8   | 29.0   | 24.2   | 27.5   | 27.4       | 28.5              |
| New Studies - Full Board (to approval)          | 64.0   | 56.0   | 46.4   | 45.5   | 43.2   | 50.0   | 54.9   | 51.0   | 52.1       | 50.6              |
| <b>Exempt</b>                                   |        |        |        |        |        |        |        |        |            | <b>Exempt</b>     |
| New Studies - Exempt (to determination)         | 48     | 45.0   | 40.0   | 28.0   | 27.0   | 27.0   | 26.67  | 28.00  | 35.4       | 32.0              |
| <b>Amendments</b>                               |        |        |        |        |        |        |        |        |            | <b>Amendments</b> |
| Amendments - Minor                              | 16.0   | 7.0    | 10.3   | 6.0    | 8.8    | 7.0    | 5.3    | 6.0    | 10.1       | 6.5               |
| Amendments - Major                              | 63.0   | 64.0   | 45.4   | 40.5   | 29.8   | 29.0   | 51.1   | 48.0   | 47.3       | 45.4              |

| Area Activities/Throughput (T) | Q1 (Jul-Sep) |            |                             | Q2 (Oct-Dec) |            |                             | Q3 (Jan-Mar) |            |                             | Q4 (Apr-Jun) |            |                             |
|--------------------------------|--------------|------------|-----------------------------|--------------|------------|-----------------------------|--------------|------------|-----------------------------|--------------|------------|-----------------------------|
|                                | Received     | Completed  | Throughput/<br>% Backlogged | Received     | Completed  | Throughput/<br>% Backlogged | Received     | Completed  | Throughput/<br>% Backlogged | Received     | Completed  | Throughput/<br>% Backlogged |
| New Studies - Full Board       | 21           | 13         | -8 (38.1%)                  | 14           | 16         | 2                           | 16           | 21         | 5                           | 17           | 16         | -1 (5.9%)                   |
| New Studies - Exempt           | 8            | 8          | 0                           | 4            | 5          | 1                           | 3            | 2          | -1 (33.3%)                  | 11           | 6          | -5 (45.5%)                  |
| Amendments - Minor             | 107          | 94         | -13 (12.1%)                 | 96           | 110        | 14                          | 84           | 75         | -9 (10.7%)                  | 151          | 147        | -4 (2.6%)                   |
| Amendments - Major             | 7            | 6          | -1 (14.3%)                  | 2            | 8          | 6                           | 9            | 5          | -4 (44.4%)                  | 7            | 8          | 1                           |
| Continuing Reviews             | 65           | 71         | 6                           | 46           | 39         | -7 (15.2%)                  | 19           | 23         | 4                           | 95           | 86         | -9 (9.5%)                   |
| <b>TOTAL</b>                   | <b>208</b>   | <b>192</b> | <b>-16 (7.7%)</b>           | <b>162</b>   | <b>178</b> | <b>16 (-9.9%)</b>           | <b>131</b>   | <b>126</b> | <b>-5 (3.8%)</b>            | <b>281</b>   | <b>263</b> | <b>-18 (6.4%)</b>           |